MediWound Ltd.
MDWD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MDWD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MDWD
MediWound Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for burn and wound care, leveraging a proteolytic enzyme platform with approved product NexoBrid and pipeline candidate EscharEx.
Key risk: Capital and liquidity risk
BioSniper Score
Based on 5 of 6 signals
Financial data as of Dec 31, 2025.
Tracking 1 pipeline candidate · 4 clinical trials · 1 catalyst · 1 FDA decision for MediWound Ltd..
MediWound Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for burn and wound care, leveraging a proteolytic enzyme platform with approved product NexoBrid and pipeline candidate EscharEx.
- MediWound's lead product NexoBrid is approved for eschar removal in severe burns, with global demand exceeding current manufacturing capabilities [sec · filed 2026-03-05].
- The company completed a new GMP-compliant manufacturing facility in August 2024, which reached full operational capacity by end of 2025, increasing output sixfold [sec · filed 2026-03-05].
- As of December 31, 2025, MediWound had cash and equivalents of $4.8M, shareholders' equity of $10.9M, and total debt of $16.9M [sec].
- MediWound reported a net loss of $23.9 million for the year ended December 31, 2025, and an accumulated deficit of $228.9 million as of that date [sec · filed 2026-03-05].
- The company received a €2.5 million grant from the European Innovation Council (EIC) Accelerator program in July 2024 to support EscharEx development [sec · filed 2026-03-05].
What works
- NexoBrid is a marketed product with growing global demand, and the company has expanded manufacturing capacity sixfold to meet that demand [sec · filed 2026-03-05].
- MediWound's proprietary proteolytic enzyme platform supports a pipeline of next-generation therapies, including EscharEx for chronic wounds and MW005 for non-melanoma skin cancer [sec · filed 2026-03-05].
- The company has secured non-dilutive funding, including a €2.5 million EIC grant, to support clinical and regulatory advancement of EscharEx [sec · filed 2026-03-05].
What to weigh
- MediWound has a history of significant net losses, with a net loss of $23.9 million in 2025 and an accumulated deficit of $228.9 million as of December 31, 2025 [sec · filed 2026-03-05].
- The company's cash position is limited ($4.8M as of 2025-12-31) and may require additional capital to fund operations and clinical development [sec].
- Product development is a lengthy and expensive process with uncertain outcomes, and success in earlier trials does not guarantee later clinical or commercial success [sec · filed 2026-03-05].
From the filings
Quoted directly from source documents.
MediWound has incurred significant net losses and accumulated deficit.
“We have incurred significant net losses, including a net loss of $23.9 million for the year ended December 31, 2025 and $30.2 million for the year ended December 31, 2024. As of December 31, 2025, we had an accumulated deficit of $228.9 million.”
SEC filings · March 5, 2026
MediWound's new manufacturing facility has increased output sixfold.
“Our new GMP-compliant state-of-the-art manufacturing facility was completed as of August 2024. The facility has reached full operational capacity by the end of 2025, increasing manufacturing output sixfold.”
SEC filings · March 5, 2026
MediWound received a €2.5 million grant from the EIC Accelerator.
“In July 2024, we were awarded a €2.5 million grant from the European Innovation Council (EIC) Accelerator program to support the clinical and regulatory advancement of EscharEx for the treatment of diabe”
SEC filings · March 5, 2026
Catalyst timeline
- 2027-03-01 · Phase3_Topline — Phase 3 Topline: A Multicenter, Prospective, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study Perf — Topline data from the Phase 3 trial of EscharEx for chronic wound debridement will be a key value inflection point.
Risks & what to watch (3)›
Key risks
- Capital and liquidity risk — Limited cash ($4.8M as of 2025-12-31) and ongoing losses may require additional financing, which could dilute shareholders [sec].
- Clinical and regulatory uncertainty — Pipeline candidates like EscharEx face lengthy, expensive development with uncertain outcomes; delays or failures are possible [sec · filed 2026-03-05].
- Manufacturing and demand mismatch — Global demand for NexoBrid currently surpasses manufacturing capabilities, though capacity expansion is underway [sec · filed 2026-03-05].
What to watch
- Phase 3 topline results for EscharEx expected in 2027-03-01 [catalyst].
- Cash runway and potential need for additional capital given limited cash reserves [sec].
- Commercial adoption and revenue growth of NexoBrid in international markets [sec · filed 2026-03-05].
- Progress of MW005 for non-melanoma skin cancer and other pipeline candidates [sec · filed 2025-03-19].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run MediWound Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MediWound Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.98
Lead: Approved
1 candidate
1 upcoming, next in ~183d
6 buys · 0 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
71
Total value held
$52.3M
| Holder | Shares | Value |
|---|---|---|
| investor ab | 872,093 | $14.0M |
| blackrock, inc. | 445,834 | $7.2M |
| meitav investment house ltd | 371,868 | $6.0M |
| sphera funds management ltd. | 273,192 | $4.4M |
| state street corp | 143,770 | $2.3M |
| ark investment management llc | 129,961 | $2.1M |
| geode capital management, llc | 121,958 | $2.0M |
| northern trust corp | 121,776 | $2.0M |
| dafna capital management llc | 94,405 | $1.5M |
| morgan stanley | 88,473 | $1.4M |
Showing top 10 of 71 institutional holders of MediWound Ltd.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 13.9%
- Days to cover
- 19.2
- Shares short
- 1,558,289
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MDWD short interestFrequently asked questions
What is the AI investment thesis for MediWound Ltd.?
MediWound Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for burn and wound care, leveraging a proteolytic enzyme platform with approved product NexoBrid and pipeline candidate EscharEx.
What is MediWound Ltd.'s lead drug candidate?
MediWound Ltd.'s most advanced tracked candidate is nexobrid (Approved).
What is MediWound Ltd.'s next catalyst?
MediWound Ltd.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Prospective, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study Perf" — expected March 1, 2027.
Who is the CEO of MediWound Ltd.?
Mr. Ofer Gonen B.Sc. is the chief executive officer of MediWound Ltd. (MDWD).
Where is MediWound Ltd. headquartered?
MediWound Ltd. (MDWD) is headquartered in Yavne, Israel.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.